NCT02848248 (Clincal Trial/ SGN-CD123A)

Study Title
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia (NCT02848248)

Trial Description
The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients This trial is sponsored by Seattle Genetics, Inc. ®

Study Data

  • Condition: Acute Myeloid Leukemia
  • Interventions:
    • Drugs used in this trial
      • SGN-CD123A
  • Phase: I
  • Enrollment: 106
  • Start: August 2016
  • Estimated Completion: June 2019
  • Last verified: September 2016
  • Last Updated: September 2016

Study Schematic


Click here to Return to Drug map

Last Editorial review: October 10, 2016
Information based on (NIH/NCI) and other sources.